Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 12:08 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 577–600 of 7,439 matching trials from the live ClinicalTrials.gov search.

Filters: Aurora, Colorado Clear all

Conditions: Acquired Immune Deficiency Syndrome (AIDS), HIV Infections
Interventions: EVG, Background regimen; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 4 Weeks to 17 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 3
States / cities: Aurora, Colorado • Durham, North Carolina • Memphis, Tennessee

Conditions: Brain Injuries, Traumatic, Sleep Initiation and Maintenance Disorders
Interventions: Not listed
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 64 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Adrenal Suppression
Interventions: Chemotherapy; Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years and older · Female only
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Hepatic Encephalopathy, Cirrhosis
Interventions: Rifaximin, Lactulose; Drug
Lead sponsor: Bausch Health Americas, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 222 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 43
States / cities: Phoenix, Arizona • Coronado, California • Fresno, California + 35 more

Conditions: Solitary Osseous Plasmacytoma
Interventions: ixazomib, lenalidomide, dexamethasone, zoledronic acid; Drug
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2025
U.S. locations: 388
States / cities: Anchorage, Alaska • Burbank, California • Clovis, California + 267 more

Conditions: Mild Cognitive Impairment
Interventions: Cannabidiol, Placebo; Drug · Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 55 Years to 85 Years
Enrollment: 236 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Metastatic Soft-tissue Sarcoma
Interventions: Cabozantinib, Nivolumab, Ipilimumab; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 4
States / cities: Stanford, California • Aurora, Colorado • St Louis, Missouri + 1 more

Conditions: Type 1 Diabetes Mellitus With Hypoglycemia
Interventions: Placebo, ZT-01, 7 mg, ZT-01, 15 mg, ZT-01, 22 mg; Drug
Lead sponsor: Zucara Therapeutics Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 186 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 38
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Escondido, California + 34 more

Conditions: Bipolar Depression
Interventions: lurasidone, Placebo; Drug
Lead sponsor: Sumitomo Pharma America, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 505 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 22
States / cities: Escondido, California • Garden Grove, California • Oceanside, California + 18 more

Conditions: Childhood Malignant Neoplasm
Interventions: Cognitive Assessment, Quality-of-Life Assessment; Procedure · Other
Lead sponsor: Children's Oncology Group; Network
Eligibility: 1 Month and older
Enrollment: 1,200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2009
U.S. locations: 163
States / cities: Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 119 more

Conditions: Type 1 Diabetes
Interventions: Insulin Pump with Continuous Glucose Monitoring; Device
Lead sponsor: Medtronic MiniMed, Inc.; Industry
Eligibility: 2 Years to 6 Years
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 8
States / cities: Palo Alto, California • San Francisco, California • Aurora, Colorado + 5 more

Conditions: Diabetes
Interventions: Insulin Guidance Software; Device
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 60 Years
Enrollment: 123 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Secondary Progressive Multiple Sclerosis
Interventions: BAF312, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 1,651 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2023
U.S. locations: 52
States / cities: Phoenix, Arizona • Berkeley, California • Los Angeles, California + 45 more

Conditions: Acute Lymphoblastic Leukemia ALL
Interventions: Ribociclib, Dexamethasone, Everolimus; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 1 Year to 30 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 12
States / cities: Aurora, Colorado • Wilmington, Delaware • Atlanta, Georgia + 7 more

Conditions: Brain Tumor, Central Nervous System Tumor
Interventions: radiation therapy; Radiation
Lead sponsor: Children's Oncology Group; Network
Eligibility: 3 Years to 20 Years
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2018
U.S. locations: 127
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 109 more

Conditions: Critical Limb Ischemia (CLI)
Interventions: Esprit BTK Device, Percutaneous Transluminal Angioplasty (PTA) Device; Device
Lead sponsor: Abbott Medical Devices; Industry
Eligibility: 18 Years and older
Enrollment: 261 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 43
States / cities: Gilbert, Arizona • Little Rock, Arkansas • Deer Park, California + 36 more

Conditions: Diabetes Mellitus, Type 2
Interventions: Canagliflozin, 100 mg, Canagliflozin, 300 mg, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 218 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 30
States / cities: Montgomery, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 27 more

Conditions: Carcinoma, Basal Cell
Interventions: CX-4945; Drug
Lead sponsor: Senhwa Biosciences, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 6
States / cities: Scottsdale, Arizona • Aurora, Colorado • Tampa, Florida + 3 more

Conditions: Congestive Heart Failure
Interventions: CRT Therapy - LV Lead Registry; Device
Lead sponsor: Biotronik, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 2,499 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2018
U.S. locations: 86
States / cities: Birmingham, Alabama • Glendale, Arizona • Mesa, Arizona + 83 more

Conditions: Advanced Lung Non-Squamous Non-Small Cell Carcinoma, Recurrent Lung Non-Squamous Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Interventions: Avelumab, Talazoparib, Talazoparib Tosylate; Drug
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: Not listed
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 325
States / cities: Mobile, Alabama • Little Rock, Arkansas • Anaheim, California + 257 more

Conditions: Metastatic Bladder Urothelial Carcinoma, Metastatic Renal Pelvis and Ureter Urothelial Carcinoma, Metastatic Ureter Urothelial Carcinoma, Stage IV Bladder Urothelial Carcinoma AJCC v7
Interventions: Berzosertib, Cisplatin, Gemcitabine Hydrochloride; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 39
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Duarte, California + 28 more

Conditions: Glycogen Storage Disease Type II, Glycogenosis 2
Interventions: Myozyme; Biological
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: Not listed
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 8
States / cities: Aurora, Colorado • Wichita, Kansas • Cambridge, Massachusetts + 5 more

Conditions: Nevi and Melanomas
Interventions: UV Counseling, UV Photo, Biological Sample; Behavioral · Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years and older
Enrollment: 71 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia, Childhood B Acute Lymphoblastic Leukemia
Interventions: Cyclophosphamide, Cytarabine, Daunorubicin Hydrochloride, Dexamethasone, Doxorubicin Hydrochloride, Leucovorin Calcium, Mercaptopurine, Methotrexate, Pegaspargase, Prednisone, Radiation Therapy, Thioguanine, Vincristine Sulfate; Drug · Radiation
Lead sponsor: Children's Oncology Group; Network
Eligibility: 1 Year to 30 Years
Enrollment: 3,154 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2021
U.S. locations: 208
States / cities: Birmingham, Alabama • Mobile, Alabama • Mesa, Arizona + 151 more

Search by objective public record fields.

Two Part Study to Evaluate Pharmacokinetics, Safety, and Antiviral Activity of Elvitegravir Administered With a PI/r Background Regimen for ARV Treatment-Experienced Pediatric Participants

The Feasibility of Home-Based Measurement of Circadian Timing for Veterans With TBI and Insomnia

Prevalence Study of Adrenal Suppression After Corticosteroids During Chemotherapy

The Safety/Efficacy of Rifaximin With/Without Lactulose in Participants With A History of Recurrent Hepatic Encephalopathy

Ixazomib Citrate, Lenalidomide, Dexamethasone, and Zoledronic Acid or Zoledronic Acid Alone After Radiation Therapy in Treating Patients With Solitary Plasmacytoma of Bone

CBD for Individuals at Risk for Alzheimer's Disease

Cabozantinib Combined With PD-1 and CTLA-4 Inhibition in Metastatic Soft Tissue Sarcoma

A Study of the Effect of ZT-01 on Night-time Hypoglycemia in Type 1 Diabetes

Lurasidone - A 6-week Study of Patients With Bipolar I Depression (Monotherapy)

Neuropsychological and Behavioral Testing in Younger Patients With Cancer

Safety Evaluation of MiniMed™ 780G System With DS5 CGM in Children

Improved Glycemic Control in Adult Subjects With Type 1 Diabetes on MDI Using Insulin Guidance Software

Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND)

Ribociclib in Combination With Everolimus and Dexamethasone in Relapsed ALL

Radiation Therapy in Treating Young Patients With Gliomas

LIFE-BTK Randomized Controlled Trial

A Study to Evaluate the Efficacy and Safety of the Addition of Canagliflozin in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin and Sitagliptin

Treatment Duration Increment and Pharmacodynamic Study of CX-4945 in Patients With Basal Cell Carcinoma (BCC)

Post Approval Registry of Corox OTW, Endocardial, Left Ventricular Steroid Lead, Bipolar

Combination Treatment (Talazoparib Plus Avelumab) for Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer With STK11 Gene Mutation (A LUNG-MAP Treatment Trial)

Cisplatin and Gemcitabine Hydrochloride With or Without Berzosertib in Treating Patients With Metastatic Urothelial Cancer

Expanded Access Use of Myozyme (Alglucosidase Alfa) in Patients With Late-onset Pompe Disease

Assessing Gene-Environment Interactions in Clinical Presentation of Nevi and Melanoma

Dexamethasone Compared With Prednisone During Induction Therapy and Methotrexate With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia